Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

@article{Bowes2012ReducingSD,
  title={Reducing safety-related drug attrition: the use of in vitro pharmacological profiling},
  author={Joanne Bowes and Andrew J Brown and Jacques Hamon and Wolfgang Jarolimek and Arun Raghav Mahankali Sridhar and Gareth J Waldron and Steven Whitebread},
  journal={Nature Reviews Drug Discovery},
  year={2012},
  volume={11},
  pages={909-922}
}
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS